Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Esperion (NASDAQ: ESPR) has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference scheduled for April 7, 2025, at 8:45 a.m. ET. The event will be accessible via webcast through Esperion's website, with replay available for approximately 90 days.
Esperion is a commercial-stage biopharmaceutical company known for developing the only FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk. Their medications are backed by the CLEAR Cardiovascular Outcomes Trial, involving nearly 14,000 patients.
The company is advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi), leveraging new insights into structure and function for rational drug design. Esperion continues to expand globally through commercial execution, international partnerships, and pre-clinical pipeline development.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ESPR gained 2.96%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
ANN ARBOR, Mich., March 24, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, at 8:45 a.m. ET.
The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When is Esperion (ESPR) presenting at the Needham Healthcare Conference 2025?
How long will Esperion's (ESPR) Needham Conference webcast be available for replay?
What are the key products that Esperion (ESPR) is currently commercializing?
How many patients were involved in Esperion's (ESPR) CLEAR Cardiovascular Outcomes Trial?
What is Esperion's (ESPR) next-generation drug development program focused on?
